ArticleBone reports2025

Impact of stopping burosumab treatment at the end of skeletal growth in adolescents with X-linked hypophosphatemia (XLH).

Charlotte Jarvis et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.